|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Hepatitis C | |||||
| Vasculitis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Hepatitis | |||||
| 3 | More general conditions related to this trial | ||||
| Cardiovascular Diseases | |||||
| Digestive System Diseases | |||||
| Flaviviridae Infections | |||||
| Hepatitis, Viral, Human | |||||
| Liver Diseases | |||||
| RNA Virus Infections | |||||
| Vascular Diseases | |||||
| Virus Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Rituximab | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Antirheumatic Agents | |||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Allergy and Infectious Diseases (NIAID) | |||||